The stock of Innoviva Inc (INVA) has gone down by -0.52% for the week, with a -4.22% drop in the past month and a -0.26% drop in the past quarter. The volatility ratio for the week is 1.67%, and the volatility levels for the past 30 days are 2.74% for INVA. The simple moving average for the last 20 days is -2.10% for INVA’s stock, with a simple moving average of 10.36% for the last 200 days.
Is It Worth Investing in Innoviva Inc (NASDAQ: INVA) Right Now?
The price-to-earnings ratio for Innoviva Inc (NASDAQ: INVA) is above average at 27.70x. The 36-month beta value for INVA is also noteworthy at 0.53. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 2 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INVA is 61.89M, and at present, short sellers hold a 18.74% of that float. The average trading volume of INVA on November 28, 2024 was 599.44K shares.
INVA) stock’s latest price update
The stock of Innoviva Inc (NASDAQ: INVA) has decreased by -0.47 when compared to last closing price of 19.14.Despite this, the company has seen a loss of -0.52% in its stock price over the last five trading days. businesswire.com reported 2024-11-26 that BURLINGAME, Calif.–(BUSINESS WIRE)–Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday,.
Analysts’ Opinion of INVA
Goldman, on the other hand, stated in their research note that they expect to see INVA reach a price target of $16. The rating they have provided for INVA stocks is “Neutral” according to the report published on July 20th, 2022.
Deutsche Bank gave a rating of “Hold” to INVA, setting the target price at $13 in the report published on November 20th of the previous year.
INVA Trading at -2.62% from the 50-Day Moving Average
After a stumble in the market that brought INVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.48% of loss for the given period.
Volatility was left at 2.74%, however, over the last 30 days, the volatility rate increased by 1.67%, as shares sank -3.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.51% lower at present.
During the last 5 trading sessions, INVA fell by -0.52%, which changed the moving average for the period of 200-days by +23.06% in comparison to the 20-day moving average, which settled at $19.46. In addition, Innoviva Inc saw 18.77% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for INVA
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.8 for the gross margin
The net margin for Innoviva Inc stands at 0.18. The total capital return value is set at 0.17. Equity return is now at value 9.97, with 5.34 for asset returns.
Based on Innoviva Inc (INVA), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.64. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 7.17.
Currently, EBITDA for the company is 248.96 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 3.27. The receivables turnover for the company is 3.99for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In summary, Innoviva Inc (INVA) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
